Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C

Area of Science:

• Immunology
• Hepatology
• Cell Biology

Background:

• Chronic hepatitis C (CHC) leads to progressive liver disease in a significant patient subset.
• Monocytes are key myeloid cells in immune responses; proinflammatory CD16+ monocytes and proangiogenic Tie-2 expressing monocytes (TEMs) are distinct subsets.
• TEMs possess significant proangiogenic potential, warranting investigation in liver disease pathogenesis.

Purpose of the Study:

• To investigate the heterogeneity of peripheral blood monocytes in CHC patients.
• To examine the role of monocyte subsets in CHC disease progression.
• To assess the impact of monocyte phenotypes on response to antiviral therapy.

Main Methods:

• Flow cytometry was used to analyze CD16+ and Tie-2 expressing monocyte subpopulations in 39 CHC patients and 21 healthy controls.
• Expression of proangiogenic and tissue remodeling factors was quantified in monocyte supernatants via ELISA and protein arrays.
• Immunofluorescence was employed to analyze intrahepatic expression of CD14, CD31, and Tie-2.

Main Results:

• Peripheral monocyte subsets with proinflammatory (CD16+) and proangiogenic (TEMs) potential were significantly increased in CHC patients (P < 0.005).
• TEMs were notably elevated in nonresponders, particularly those with lower CD16 expression.
• Angiogenic factors like angiopoietin-1 and angiogenin were differentially expressed by monocytes; intrahepatic TEMs were identified in portal infiltrates of CHC patients.

Conclusions:

• Peripheral monocyte phenotypes are relevant to achieving treatment response in CHC.
• The study highlights the potential of monocyte subset regulation for improving CHC prognoses.
• Targeting monocyte subsets may offer novel adjuvant therapeutic strategies for CHC.